Jingsong Wang,
MD

Dr. Wang is currently an advisor for Atlas Venture after serving as  the Head of China Research and Development and Head of Translational Medicine, Asia Pacific, for Sanofi. Previously, Dr. Wang worked at Bristol-Myers Squibb Co., where he served in  multiple roles with increasing responsibilities, including Director of Discovery Medicine & Clinical Pharmacology, Medical Lead for the Orencia product renew team, Lead for the global Exploratory Development Team, and Liaison to China Research and Development.

Dr. Wang was Associate Director and Head for Translational Medicine and Biomarker Development in the Inflammation and Rheumatologic Disease Area at Wyeth (now Pfizer). Prior to that, he worked at Brigham and Women’s Hospital. Dr. Wang completed his clinical rheumatology fellowship and was an attending rheumatologist and faculty member at Harvard Medical School, and also completed a research fellowship at the Harvard School of Public Health.

Dr. Wang has published in numerous leading scientific journals and authored a number of textbook chapters related to inflammation, autoimmune diseases, and translational medicine. He is board certified in rheumatology and a diplomate of the American Board of Internal Medicine.

Dr. Wang’s academic appointments include visiting professorships in China, as an Adjunct Assistant Professor of Medicine at University of Pennsylvania, and as an attending physician at the Hospital of the University of Pennsylvania. He is on the Research Grant Review Committee for the National Natural Science Foundation of China, and has served as a Scientific Grant Reviewer on the Medical Research Council (UK), the National Institute for Health Research (UK), the UK National Health Service, and as member of the expert panel for the Biotechnology Industry Organization’s US congressional staff briefing on biotechnology and autoimmune diseases.